Literature DB >> 15125474

A patient with myelofibrosis complicated by refractory ascites and portal hypertension: to tips or not to tips? A case report with discussion of the mechanism of ascites formation.

R Wiest1, U Strauch, H Wagner, M Strotzer, M Woenckhaus, G Schröder, J Schölmerich, G Lock.   

Abstract

In patients with myelofibrosis, clinically significant portal hypertension is known to be predominantly presinusoidal; however, the exact mechanisms are still controversial. The pathophysiology is particularly enigmatic in those patients without histological and angiographic evidence of significant intra- or extrahepatic obstruction to portal blood flow, respectively. Moreover, ascites formation has been reported in such cases, but in general is rare in presinusoidal portal hypertension. Here we present such a patient in which ascites developed even in the presence of unchanged serum protein levels (oncotic pressure) and was refractory to sodium restricted diet and high-dose diuretic treatment. A discussion on the parameters influencing fluid exchange and ascites formation particularly emphasizing the potential importance of the hyperdynamic circulation in this case is given. Finally, the patient was treated by implanting a transjugular intrahepatic shunt (TIPS), exerting a diuretic effect sufficient enough to avoid re-formation of ascites for several months. However, ascites re-accumulated potentially due to the appearance of ectopic peritoneal myeloid metaplasia and the patient died soon afterwards. In conclusion, TIPS may be considered as rescue management for refractory ascites secondary to portal hypertension, but caution in respect to the presence and/or development of peritoneal or other ectopic haematopoesis has to be taken.

Entities:  

Mesh:

Year:  2004        PMID: 15125474     DOI: 10.1080/00365520310007521

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  7 in total

1.  Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension.

Authors:  Matthew Yan; Holly Geyer; Ruben Mesa; Ehab Atallah; Jeannie Callum; Justyna Bartoszko; Karen Yee; Manjula Maganti; Florence Wong; Vikas Gupta
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-06-11

2.  Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension.

Authors:  Christopher R Reilly; Daria V Babushok; Karlyn Martin; Jerry L Spivak; Michael Streiff; Ranjeeta Bahirwani; Jeffrey Mondschein; Brady Stein; Alison Moliterno; Elizabeth O Hexner
Journal:  Am J Hematol       Date:  2017-07-26       Impact factor: 10.047

3.  Portal hypertension secondary to myelofibrosis with myeloid metaplasia: a study of 13 cases.

Authors:  Mohannad Abu-Hilal; Jayant Tawaker
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

4.  Intestinal obstruction caused by extramedullary hematopoiesis and ascites in primary myelofibrosis.

Authors:  Xiu-Qing Wei; Zong-Heng Zheng; Yi Jin; Jin Tao; Kodjo-Kunale Abassa; Zhuo-Fu Wen; Chun-Kui Shao; Hong-Bo Wei; Bin Wu
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

5.  Nontuberculous mycobacterial infection in a patient with myelofibrosis: case report and concise review.

Authors:  Cesar Henriquez-Camacho; Pilar Martinez-Barranco; Maria Velasco; Paola Villafuerte-Gutierrez; Juan Losa
Journal:  Clin Case Rep       Date:  2015-04-09

6.  Cytodiagnosis of extramedullary hematopoiesis in serous effusion: A rare presentation unfolding the underlying etiology.

Authors:  Manjari Kishore; Prajwala Gupta; A K Malhotra; Vijay Kumar; Sanchit Singh; Minakshi Bhardwaj
Journal:  Cytojournal       Date:  2018-07-13       Impact factor: 2.091

7.  Clinical characteristics of portal hypertension complicated by gastroesophageal varices in patients with myeloproliferative neoplasms.

Authors:  Jaejun Lee; Pil Soo Sung; Ki-Seong Eom; Hyun Yang; Soon Kyu Lee; Aung Hlaing Bwa; Angelo Lozada; Jeong Won Jang; Si Hyun Bae; Jong Young Choi; Seung Kew Yoon
Journal:  Clin Mol Hepatol       Date:  2019-11-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.